Skip to main content
. Author manuscript; available in PMC: 2022 Jul 2.
Published in final edited form as: Antiviral Res. 2021 May 24;191:105090. doi: 10.1016/j.antiviral.2021.105090

Fig 2. CCHFV RNA levels in blood and tissues of VRP-vaccinated IFNAR−/− mice.

Fig 2.

Mice were vaccinated SC with VRP (back-titer dose: 2 × 104 TCID50) and subsequently challenged SC at the indicated timepoints with CCHFV Turkey-200406546 (back-titer dose: 24 TCID50). Two unvaccinated control groups were challenged in parallel, one with the same dose of inoculum (24 TCID50) as vaccinated groups, and the other with a 10-fold dilution of the inoculum (2.4 TCID50). CCHFV S genome RNA levels were assessed in blood and tissues collected when mice reached end-point criteria (fatal; 5–8 dpi) or at completion of the study (survivors; 21 dpi). ND, not detected. Bars indicate mean levels.